| Change Notification | Applies to: * | Date | ||||||
|---|---|---|---|---|---|---|---|---|
| BM-DSG | CB-DSG | GDRI | TD-DSG | TL-DSG | WB-DSG | Red Book | ||
| No. 52 - 2024 WNV in France |
⬤ | 26.11.24 | ||||||
| No. 51 - 2024 Migraine and Topiramate |
⬤ | 26.11.24 | ||||||
| No. 50 - 2024 Updates in the GDRI |
⬤ | 28.10.24 | ||||||
| No. 49 - 2024 Monoclonal Antibody Therapies |
⬤ | 26.11.24 | ||||||
| No. 48 - 2024 Haemolytic Anaemia |
⬤ | 26.11.24 | ||||||
| No. 47 - 2024 Topical Anti-Androgens |
⬤ | 26.11.24 | ||||||
| No. 46 - 2024 COVID-19 Vaccination |
⬤ | 26.11.24 | ||||||
| No. 45 - 2024 Hepatitis A |
⬤ | ⬤ | 26.11.24 | |||||
| No. 44 - 2024 Dengue in France, Italy, Iran and UAE |
⬤ | 07.10.24 | ||||||
| No. 43 - 2024 Links to Immunodeficiency entry in WB-DSG |
⬤ | 07.10.24 | ||||||
| No. 42 - 2024 Dengue Risk in France |
⬤ | 31.07.24 | ||||||
| No. 41 - 2024 Malaria Risk in Costa Rica |
⬤ | 31.07.24 | ||||||
| No. 40 - 2024 West Nile Virus |
⬤ | 13.08.24 | ||||||
| No. 39 - 2024 Weight |
⬤ | 13.08.24 | ||||||
| No. 34 - 2024 Vitamin Treatment |
⬤ | 13.08.24 | ||||||
| No. 33 - 2024 Tuberculosis |
⬤ | ⬤ | 13.08.24 | |||||
| No. 32 - 2024 Necrotising Fasciitis |
⬤ | 13.08.24 | ||||||
| No. 31 - 2024 Acute Infection |
⬤ | 13.08.24 | ||||||
| No. 30 - 2024 Cerebrovascular Disease and Intracranial Haemorrhage |
⬤ | 07.10.24 | ||||||
| No. 29 - 2024 Human Plasma for Fractionation, LD |
⬤ | 17.05.24 | ||||||
| No. 28 - 2024 Donor Adverse Events - Severity Grading |
⬤ | 07.10.24 | ||||||
| No. 27 - 2024 Platelet Disorders |
⬤ | 07.10.24 | ||||||
| No. 26 - 2024 Faints |
⬤ | 31.07.24 | ||||||
| No. 25 - 2024 Dental Treatment |
⬤ | 31.07.24 | ||||||
| No. 24 - 2024 Yellow Fever and Dengue Risk |
⬤ | 31.07.24 | ||||||
| No. 23 - 2024 Sexually Transmitted Disease |
⬤ | 18.04.24 | ||||||
| No. 22 - 2024 Upper Age Limit for Returning Donors |
⬤ | ⬤ | 31.07.24 | |||||
| No. 21 - 2024 Cardiovascular Disease |
⬤ | 31.07.24 | ||||||
| No. 20 - 2024 Bleeding Disorder |
⬤ | 31.07.24 | ||||||
| No. 19 - 2024 Pyrexia and Infection |
⬤ | 31.07.24 | ||||||
| No. 18 - 2024 Animal Bite (Non-Human) |
⬤ | 31.07.24 | ||||||
| No. 17 - 2024 Osteoarthritis |
⬤ | 31.07.24 | ||||||
| No. 16 - 2024 Drugs and Platelet Donation |
⬤ | 31.07.24 | ||||||
| No. 15 - 2024 Shunts, Stents and Devices |
⬤ | 31.07.24 | ||||||
| No. 14 - 2024 Fertility |
⬤ | 31.07.24 | ||||||
| No. 13 - 2024 Tropical Viruses |
⬤ | ⬤ | ⬤ | 18.04.24 | ||||
| No. 12 - 2024 Ankylosing Spondylitis and Eye Disease |
⬤ | 18.04.24 | ||||||
| No. 11 - 2024 Cerebrovascular Disease and CNS Disease |
⬤ | 18.04.24 | ||||||
| No. 10 - 2024 Coronavirus Vaccination |
⬤ | ⬤ | ⬤ | ⬤ | 18.04.24 | |||
| No. 09 - 2024 Transgender and Non-Binary Donors |
⬤ | 18.04.24 | ||||||
| No. 08 - 2024 Travel Criteria for Plasmapheresis Donors |
⬤ | 02.05.24 | ||||||
| No. 07 - 2024 Immunosuppression |
⬤ | 02.05.24 | ||||||
| No. 06 - 2024 Hepatitis A and Human Parvovirus B19 |
⬤ | 18.04.24 | ||||||
| No. 05 - 2024 Chapter 21 and Annexe 7 of the Red Book |
⬤ | 18.04.24 | ||||||
| No. 04 - 2024 Updates in the GDRI |
⬤ | 04.04.24 | ||||||
| No. 03 - 2024 Red Book Updates, Batch 3 |
⬤ | 13.03.24 | ||||||
| No. 02 - 2024 Tropical Virus Risks in the GDRI |
⬤ | 05.02.24 | ||||||
| No. 01 - 2024 Coronavirus Infection (COVID-19) |
⬤ | 29.01.24 | ||||||
| No. 38 - 2023 Splenectomy & ITP |
⬤ | 29.01.24 | ||||||
| No. 37 - 2023 Gout |
⬤ | 29.01.24 | ||||||
| No. 36 - 2023 Adrenal Failure |
⬤ | 29.01.24 | ||||||
| No. 35 - 2023 Eye Disease |
⬤ | ⬤ | 29.01.24 | |||||
(*)
BM-DSG - Bone Marrow and Peripheral Blood Stem Cell Donor Selection Guidelines
CB-DSG - Cord Blood Donor Selection Guidelines
GDRI - Geographical Disease Risk Index
TD-DSG - Tissue (Deceased) Donor Selection Guidelines
TL-DSG - Tissue (Live) Donor Selection Guidelines
WB-DSG - Whole Blood and Components Donor Selection Guidelines
Red Book - Guidelines for the Blood Transfusion and Tissue Transplantation Services in the UK